(Q38630561)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558498%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558498%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558498%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

4

F Stephen Hodi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558498%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Kevin J Harrington

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558498%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

J Randolph Hecht

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558498%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Zsolt Szabo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558498%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Swami Murugappan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558498%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Howard L Kaufman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558498%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

1 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558498%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

29 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558498%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558498%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558498%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

1389-1403

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558498%20AND%20SRC:MED&resulttype=core&format=json

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

29 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Metastatic melanoma - a review of current and future treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Intralesional therapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Treating advanced melanoma: current insights and opportunities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Recent progress in the battle between oncolytic viruses and tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

21 January 2018

Oncolytic virotherapy

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Herpes simplex virus 1 (HSV-1) for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Oncolytic herpes simplex virus type 1 and host immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Biosafety of gene therapy vectors derived from herpes simplex virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Oncolytic biotherapy: a novel therapeutic plafform

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Thunder and lightning: immunotherapy and oncolytic viruses collide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

GM-CSF-secreting melanoma vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Immune checkpoint modulation: rational design of combination strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Going viral with cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Gauging the Long-Term Benefits of Ipilimumab in Melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Combinatorial approach to treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

Bevacizumab plus ipilimumab in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1115725

10.1586/14737140.2015.1115725

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558498%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference